Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–182 of 182 matching trials from the live ClinicalTrials.gov search.
Conditions
Burnout, Burnout, Healthcare Workers
Interventions
Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate, Real-time Biofeedback
Drug · Device
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Completed Phase 1 Interventional Accepts healthy volunteers

Consciousness, Psilocybin, and Well-Being

NCT05592379
Conditions
Healthy, Psychedelic Experiences, Sleep
Interventions
Psilocybin, Clonidine, Saline
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Alcohol Dependence
Interventions
Psilocybin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
25 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Recruiting Phase 1 Interventional Accepts healthy volunteers

Open-Label Psilocybin Study in Transdiagnostic Population

NCT06442423
Conditions
Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Completed Phase 2 Interventional Results available

Effects of Psilocybin in Major Depressive Disorder

NCT03181529
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Fibromyalgia
Interventions
Psilocybin, Psychotherapy
Drug · Behavioral
Lead sponsor
Kevin Boehnke
Other
Eligibility
25 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Conditions
Major Depression
Interventions
Psilocybin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Portland, Oregon + 2 more
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot RECAP Study in Healthy Volunteers

NCT04842045
Conditions
Psychedelic Experiences, Amnesia
Interventions
Psilocybin and Midazolam
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Active, not recruiting Phase 1 Interventional

A Study of Psilocybin for PTSD

NCT06407635
Conditions
Post Traumatic Stress Disorder
Interventions
Psilocybin, Trauma-focused psychotherapy, Standard psychological support
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Not yet recruiting Phase 2 Interventional

Group PACBT for Depression

NCT07566104
Conditions
Depression - Major Depressive Disorder, Psilocybin, Cognitive Behavioral Therapy
Interventions
Psilocybin (drug), Group Cognitive Behavioral Therapy
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Hospice, Psilocybin, Demoralization, Terminal Illness, Cancer-related Problem/Condition, Psychotherapy, Terminal Cancer, Cancer Terminal
Interventions
Psilocybin, Psychotherapy
Drug · Behavioral
Lead sponsor
Yvan Beaussant, MD, MSci
Other
Eligibility
21 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Danvers, Massachusetts
Conditions
Post-Traumatic Headache
Interventions
Placebo oral capsule, Low Dose Psilocybin, High Dose Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
PTSD
Interventions
Psilocybin 15mg, Psilocybin 25mg
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas